Loading…
Onyx Biotec (ONYX)₹34.00−1.73%Pharmaceuticals
At the end of the Mar 2026 quarter, Onyx Biotec's shareholders were: promoters 65.16%, FIIs 1.06%, DIIs 2.41%, public 31.37%. Promoter holding is unchanged on the quarter. 0.00% of promoter shares were pledged. It had 585 shareholders.
As of · Company filings (shareholding pattern)
| Dec 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|
| Promoters | 65.16% | 65.16% | 65.16% | 65.16% |
| FIIs | 8.69% | 5.33% | 1.94% | 1.06% |
| DIIs | 3.32% | 2.41% | 2.41% | 2.41% |
| Public | 22.83% | 27.10% | 30.49% | 31.37% |
| Promoter shares pledged | — | — | — | 0.00% |
| Number of shareholders | 1,180 | 550 | 639 | 585 |
| Holder | Category | Mar 2026 | Change (pp) |
|---|---|---|---|
| Naresh Kumar | Promoter | 23.93% | — |
| Sanjay Jain | Promoter | 21.49% | — |
| Fateh Pal Singh | Promoter | 19.65% | — |
| Invicta Continuum Fund I | DII | 2.41% | — |
| Apneet Kahlon | Public | 1.64% | — |
| Prognosis Securities Private Limited | Public | 1.53% | — |
| Invicta Capserv | Public | 1.53% | — |
| Kadayam Ramanathan Bharat | Public | 1.09% | — |
Promoters held 65.16% of Onyx Biotec at the end of the Mar 2026 quarter.
In the Mar 2026 quarter, foreign institutional investors (FIIs) held 1.06% (down 0.88 percentage points from 1.94% a quarter earlier) and domestic institutions (DIIs) held 2.41% (unchanged at 2.41% a quarter earlier).
No. The Mar 2026 filing shows no pledged promoter shares.
Onyx Biotec had 585 shareholders at the end of the Mar 2026 quarter.
Invicta Continuum Fund I (DII) held 2.41% at the end of the Mar 2026 quarter, the largest named holding outside the promoter group.